Conference Menu 

Overview
Register
Day 1
Day 2
Day 3
Pre-Conference Events
Short Courses
Post-Conference Event
Speaker Biographies
Download Brochure
Hotel & Travel
Sponsor & Exhibit
Posters
Podcasts
Press Pass
Request Information 

 

   

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

About the Conference 

Tumor collections provide insight into the great variability of cancer, its progression and its response to treatment. Patient xenografts (PDX) and cell models allow researchers to link and integrate information and determine personal variations in cancer molecular profiles. The recent advancements in high-throughput genomics, proteomics and other -omics platforms allow profiling of large numbers of cancer analytes in a single assay. Thus, knowledge of these altered molecular landscapes offers great promise for developing molecular tests to improve cancer diagnosis and optimize treatment. Cambridge Healthtech Institute’s Inaugural Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change convenes international oncology experts in the fields of tumor biospecimen research, PDX models, molecular diagnostics/prognostics and pharmacogenomics.

 

Keynote Speakers:  Carolyn Compton, M.D., Ph.D.  National Biomarkers Development Alliance, Complex Adaptive Systems Institute, Mayo Medical School and Arizona State University James M. Olson, M.D., Ph.D.  Fred Hutchinson Cancer Research Center, University of Washington, Seattle Children’s Hospital, Presage Biosciences and Blaze Bioscience Nathan D. Price, Ph.D.  Institute for Systems Biology John T. Slattery, Ph.D.   University of Washington School of Medicine

Sunday, September 14  Complimentary Onsite Laboratory Tour and Reception: University of Washington's Center for Cancer Innovation  Tuesday, September 16  Short Course: What It Takes to Be a Biobanking Operations Manager: From Patient Interaction to Freezer Inspection  Thursday, September 18  Seminar: Informed Consent Content & Process Requirements for Biobanking Studies